Databricks Unifies Clinical Data
Databricks' new open-source Site Feasibility Workbench brings clinical trial intelligence onto its Lakehouse, tackling data silos and improving auditability.

Visual TL;DR
From the article 4 mentionsThe perennial problem of clinical trial delays, where nearly half of investigator sites miss enrollment targets, stems not from a lack of tools but from a fundamental architectural flaw: disconnected data.
fundamental architectural flaw in traditional systems
From the article 9+ mentionsThe perennial problem of clinical trial delays, where nearly half of investigator sites miss enrollment targets, stems not from a lack of tools but from a fundamental architectural flaw: disconnected data.
unified platform for data and models
From the article 9 mentionsDatabricks is aiming to fix this with its new open-source Site Feasibility Workbench, which places clinical operations intelligence directly on its Lakehouse platform.
open-source tool for clinical intelligence
From the article 4 mentionsThe Site Feasibility Workbench trains machine learning models on an organization's own clinical trial data, CTMS, EDC, and IRT history, for more precise predictions.
From the articleThis approach eliminates the costly integration overhead, credential sprawl, and synchronization lag that plague traditional clinical trial operations.
data lives where decisions are made
addresses under-enrollment and financial losses
Contents(4)
© 2026 StartupHub.ai. All rights reserved. You may not republish this article in full without a license. Search engines and AI research tools may crawl and summarize for reference. Bulk reproduction or model training requires a license. See our terms.
Written by
Daniel SingerEditor, StartupHub.ai
Daniel Singer is the editor of StartupHub.ai, a technology expert and thought leader on AI and its applications across sectors, from fintech and healthcare to developer tooling and consumer software. He writes and tests the tools covered here thoroughly and regularly, and built StartupHub.ai to give founders, operators and buyers a clearer read on what they are actually being sold.
More from Daniel Singer